

Press
release

Montpellier, France, January 24, 2022 – 5.45pm CET

Intrasense: ambitions and publication calendar for 2022

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian®, hereby sets out its ambitions, development plan and financial publication timetable for 2022.

Growth through innovation

Intrasense is pursuing its development plan, driven by its innovation-based strategy and supported by its successful capital increase of June 2021. The Company intends to achieve growth in its key markets – Europe and China – in the fields of radiology and oncology.

The future Myra range of oncology products, presented in June 2021, is currently in the definition and development phase. Intrasense's teams are working closely with major clinical players in the oncology segment, such as the I-SERIS group, on defining and validating the future platform's functionalities. Other major R&D partnerships are currently being finalised and will be announced to the market in the coming weeks.

Myrian® enhanced with artificial intelligence (AI)

The Company is continuing to improve its Myrian® product range by providing radiologists with leading-edge clinical tools and enhanced functionality, resulting in particular from the use of AI.

Integrating AI algorithms into clinicians' routines, as part of a fluid workflow that is ideally suited to user needs, lies at the heart of Intrasense's vision.

New solutions, such as those developed in partnership with MeVis to treat lung diseases, will be available in version 2.10 of Myrian®. This new version will be subject to the new European medical device regulation in the first half of 2022, and brought to market thereafter.

Ambitious growth targets in Europe and China

After its June 2021 capital increase, Intrasense adopted an ambitious development plan. The Group is aiming to increase its market share in France, develop new markets in Europe and accelerate its growth in China. To support that aim, a number of talented sales and marketing staff members have joined Intrasense in the last few months to underpin its growth momentum in the years to come. Geographical sales organisations, closer to customers, are being rolled out this year.

Improved visibility for 2022

Intrasense will have many opportunities to meet with medical imaging and oncology professionals this year.

The Company's teams will take part in Arab Health 2022 at the World Trade Center in Dubai from 24 to 27 January. This medical equipment exhibition is the largest in the Middle East, and will give Intrasense's teams the opportunity to increase the Group's international presence.

The Company will also take part in the China International Medical Equipment Fair (CMEF) in Shanghai between 7 and 10 April 2022, raising its profile among healthcare and medical imaging professionals.

Finally, Intrasense will take part in several events in France, such as the *Journées Francophones de Scanner* and the *Journées Francophones de Radiologie* in October.

Annual results publication calendar

Intrasense will announce its 2021 annual results on 10 March 2022¹. It intends to publish its annual financial report for the year ended 31 December 2021 on 20 April 2022¹.

¹ This timetable is indicative and may be adjusted.



About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense
Anne-Elisabeth Achiri
Communications Officer
Tel: +334 67 13 01 30
investor@intrasense.fr

NewCap
Olivier Bricaud
Investor Relations and
Financial Communication
Tel: +331 44 71 20 40
intrasense@newcap.eu

